Q2 2023 EPS Estimates for Co-Diagnostics, Inc. Cut by Litchfield Hills Research (NASDAQ:CODX)

Co-Diagnostics, Inc. (NASDAQ:CODX – Get Rating) – Investment analysts at Litchfield Hills Research lowered their Q2 2023 EPS estimates for Co-Diagnostics in a research note issued on Tuesday, May 16th. Litchfield Hills Research analyst T. O’neill now forecasts that the company will earn ($0.23) per share for the quarter, down from their previous forecast of ($0.19). The consensus estimate for Co-Diagnostics’ current full-year earnings is ($0.84) per share. Litchfield Hills Research also issued estimates for Co-Diagnostics’ Q3 2023 earnings at ($0.23) EPS, Q4 2023 earnings at ($0.21) EPS, FY2023 earnings at ($0.87) EPS, Q1 2024 earnings at ($0.20) EPS, Q2 2024 earnings at ($0.20) EPS, Q3 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.12) EPS and FY2024 earnings at ($0.66) EPS.

CODX has been the topic of several other research reports. TheStreet lowered Co-Diagnostics from a “c-” rating to a “d” rating in a research note on Monday, April 10th. HC Wainwright downgraded shares of Co-Diagnostics from a “buy” rating to a “neutral” rating in a research note on Monday, March 20th.

Co-Diagnostics Trading Down 0.7 %

CODX stock opened at $1.34 on Thursday. Co-Diagnostics has a 1-year low of $1.20 and a 1-year high of $7.13. The business’s 50 day moving average is $1.62 and its 200-day moving average is $2.50. The firm has a market cap of $40.55 million, a P/E ratio of -1.34 and a beta of -0.91.

Institutional Trading of Co-Diagnostics

A number of hedge funds and other institutional investors have recently made changes to their positions in CODX. Renaissance Technologies LLC lifted its position in Co-Diagnostics by 99.0% during the 1st quarter. Renaissance Technologies LLC now owns 586,052 shares of the company’s stock worth $3,622,000 after buying an additional 291,552 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Co-Diagnostics by 4.3% during the first quarter. Vanguard Group Inc. now owns 1,871,914 shares of the company’s stock valued at $11,568,000 after purchasing an additional 76,857 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Co-Diagnostics by 1,277.7% in the first quarter. Acadian Asset Management LLC now owns 78,212 shares of the company’s stock valued at $482,000 after purchasing an additional 72,535 shares in the last quarter. Bank of Montreal Can bought a new position in Co-Diagnostics in the 2nd quarter worth approximately $349,000. Finally, Engineers Gate Manager LP lifted its holdings in Co-Diagnostics by 89.2% during the 1st quarter. Engineers Gate Manager LP now owns 122,003 shares of the company’s stock worth $754,000 after buying an additional 57,508 shares in the last quarter. 20.33% of the stock is currently owned by institutional investors and hedge funds.

Co-Diagnostics Company Profile

(Get Rating)

Co-Diagnostics, Inc engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.